부산대학교 도서관

Mosunetuzumab induces complete remissions in poor prognosis Non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T-Cell (CAR-T) therapies, and is active in treatment through multiple lines. While early clinical trials of CAR T-cell therapy focused on the maximum grade, it is now recognized that cytopenias post CAR T-cell therapy occur in a biphasic manner [[8]]. In this issue of Leukemia and Lymphoma, Brudno and colleagues report risk factors associated with acute and delayed cytopenias on three clinical trials of investigational autologous and allogeneic CAR T-cell therapies [[1]], adding to the growing body of literature regarding this common and poorly understood toxicity of immunotherapy. This phenomenon is not unique to autologous CAR T-cell therapy, but is also known to occur with allogeneic CAR T-cell therapies, other immune effector cell therapies such as CAR-NK [[3]], and other immune-activating drugs such as bispecific antibodies [[4], [6]]. [Extracted from the article]